Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South.

    Apr 30, 2026DOI: 10.1093/cid/ciaf425Journal ArticleCID

    Written by: Jonathan A ColasantiAmalia AldredgeLarisa V Niles-CarnesEudiah OchiengPriyasha PareekVickie RobinsonErica AndersonMary CastanedaHilary SprallingBradley L SmithJeri SumitaniEric Paul LeueCaitlin A MoranMeredith LoraWendy S ArmstrongLauren F Collins

    Find these authors on Roon

    WA
    Dr. Wendy Armstrong
    HIV/AIDS Medicine · University of Colorado

    Summary

    BACKGROUND: People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in the highest HIV burden areas.METHODS: We performed a retrospective review of PWH who initiated LA-ART (cabotegravir/rilpivirine [CAB/RPV] ± lenacapavir [LEN] ± ibalizumab [IBA]) with viremia (≥50 c/mL) at a Ryan White-funded program in the urban South between 14 April 2021 and 31 August 2024. Among PWH who received ≥3 LA-CAB/RPV injections through end of follow-up (31 December 2024), achieving VS (<50 c/mL) was assessed.RESULTS: Eighty-one PWH with viremia initiated LA-ART. Among them, 93% identified as Black, 40% were cis-/trans-women, the median (Q1-Q3) age was 38 (30-49) years, and the median income was $25K/year ($20-33K/year). The median (Q1-Q3) time since HIV diagnosis was 15.5 (8.8-20.5) years, and 46% had prior opportunistic conditions. At LA-ART initiation (56 CAB/RPV; 22 CAB ± RPV + LEN; 3 CAB ± RPV + LEN + IBA), the median (Q1-Q3) viral load was 4.0 (2.9-4.8) log10 and CD4 + 186 (62-420) cells/μL. Of 79 PWH who remained engaged, 73 (92%) achieved VS after a median (Q1-Q3) of 1 (1-2) injection, with CD4 rise to 353 (187-501) cells/μL. Otherwise, 2 had virologic failure with drug resistance; 4 had persistent viremia without resistance (>200 c/mL [n = 2]; 50-200 c/mL [n = 2]). Of 645 LA-CAB/RPV injections (500 Q4wk; 145 Q8wk), 635 (98%) were administered on-time; all LEN (43/43) and IBA (37/37) administrations occurred on-time.CONCLUSIONS: In the largest southern US cohort of PWH with viremia initiating LA-ART, 92% achieved VS despite significant barriers to care and disease burden, underscoring LA-ART as a tool to help achieve Ending the HIV Epidemic goals.
    WADr. Wendy Armstrong

    Dr. Wendy Armstrong

    Infectious Disease · HIV & AIDS Medicine
    University of Colorado School of Medicine
    wendya